Adaptimmune Therapeutics (ADAP) Tops Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Adaptimmune Reports Third Quarter 2016 Financial Results
November 10, 2016 6:30 AM ESTU.S. Food and Drug Administration (FDA) lifted partial clinical hold of myxoid/round cell liposarcoma (MRCLS) study of NY-ESO SPEAR T-cell therapy; initiation of screening expected in 4Q 2016
Initiated first site for triple tumor study with wholly-owned MAGE-A10 SPEAR T-cells
Initiated new patient cohort in synovial sarcoma NY-ESO program
Started recruitment of additional patients under amended protocol in ovarian NY-ESO program
Executed key agreements with Merck, PCT, and The MD Anderson Cancer Center
Adaptimmune reaffirms financial guidance
Conference call to be held today at... More
Adaptimmune Announces Removal of Partial Clinical Hold in Myxoid/Round Cell Liposarcoma (MRCLS)
November 9, 2016 4:05 PM ESTPHILADELPHIA and OXFORD, United Kingdom, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration has removed the partial clinical hold on the planned study of its NYESO SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell therapy in MRCLS.
Under a revised protocol, Adaptimmune will initiate a study in up to 15 MRCLS patients. Patient screening is expected to begin in 4Q 2016. Results from this study will inform a potential future registration trial.
... More